TY  - GEN
AU  - Borgia,Sergio M
AU  - Dearden,Janet
AU  - Yoshida,Eric M
AU  - Shafran,Stephen D
AU  - Brown,Ashley
AU  - Ben-Ari,Ziv
AU  - Cramp,Matthew E
AU  - Cooper,Curtis
AU  - Foxton,Matthew
AU  - Rodriguez,Conrado Fernandez
AU  - Esteban,Rafael
AU  - Hyland,Robert
AU  - Lu,Sophia
AU  - Kirby,Brian J
AU  - Meng,Amy
AU  - Markova,Svetlana
AU  - Dvory-Sobol,Hadas
AU  - Osinusi,Anu O
AU  - Bruck,Rafael
AU  - Ampuero,Javier
AU  - Ryder,Stephen D
AU  - Agarwal,Kosh
AU  - Fox,Raymond
AU  - Shaw,David
AU  - Haider,Shariq
AU  - Willems,Bernard
AU  - Lurie,Yoav
AU  - Calleja,Jose Luis
AU  - Gane,Edward J
TI  - Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
SN  - 1600-0641
PY  - 2020///1207
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Carbamates
KW  - Drug Combinations
KW  - Drug Monitoring
KW  - methods
KW  - Female
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - complications
KW  - Heterocyclic Compounds, 4 or More Rings
KW  - Humans
KW  - Kidney Failure, Chronic
KW  - Liver Cirrhosis
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Renal Dialysis
KW  - Sofosbuvir
KW  - Sustained Virologic Response
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.jhep.2019.05.028
ER  -